Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Evolvere BioSciences
AddedJun 25, 2026
UpdatedJul 2, 2026
Evolvere BioSciences

Evolvere BioSciences

Seed

Making Next-Generation Antibiotics that Outpace Bacterial Evolution.

HQ
Oxford, GB
Accelerator
Y Combinator logoY CombinatorS24
Overview
Compare
Fundraising
Employees
Website

🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them.

This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩‍⚕️.

Evolvere BioSciences - Similar Companies

Anto Biosciences logo

Anto Biosciences

anto.bio

FinalDose logo

FinalDose

finaldose.ai

Convexia logo

Convexia

convexia.bio

CellType logo

CellType

celltype.com

Ditto Biosciences logo

Ditto Biosciences

dittobio.com

AbInitio Bio logo

AbInitio Bio

abinitio-bio.com

10x Science logo

10x Science

10xscience.com

Exonic logo

Exonic

exonic.ai

BioStack Platforms logo

BioStack Platforms

getbiostack.com

Anthrogen logo

Anthrogen

anthrogen.com

AminoAnalytica logo

AminoAnalytica

aminoanalytica.com

Blank Bio logo

Blank Bio

blank.bio

Prana logo

Prana

pranadoc.com

Exin Therapeutics logo

Exin Therapeutics

Synthio Labs logo

Synthio Labs

synthiolabs.com

Evolvere BioSciences - Quick Facts

Who are Evolvere BioSciences' competitors?

Companies similar to Evolvere BioSciences include Anto Biosciences, FinalDose, Convexia and CellType.

Where is Evolvere BioSciences' headquarters located?

Evolvere BioSciences' headquarters is located in Oxford, GB.

When was Evolvere BioSciences' last funding round?

Evolvere BioSciences' most recent funding round was for $500k (USD) in June 2024.

How much has Evolvere BioSciences raised to-date?

As of Jun 1, 2024, Evolvere BioSciences has raised a total of $500k (USD).